3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
2
Melanoma
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
Sunitinib
145
Nivolumab
144
pembrolizumab
132
Sorafenib
84
Bevacizumab
77
Everolimus
74
cabozantinib
71
pazopanib
65
Axitinib
65
Ipilimumab
62
aldesleukin
52
Magnetic Resonance Spectroscopy
45
Cyclophosphamide
40
Interleukin-2
38
lenvatinib
37
Specimen Handling
36
Radiosurgery
36
Interferon-alpha
32
atezolizumab
30
temsirolimus
27
belzutifan
24
Gemcitabine
23
fludarabine phosphate
22
avelumab
22
Radiotherapy
19
Interferon alpha-2
19
Biopsy
18
fludarabine
17
durvalumab
17
Nephrectomy
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Patient Reported Outcome Measures
×
Genitourinary
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled